Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded May 26, 2026 · Filed May 28, 2026
Incyte's Principal Accounting Officer sold $200K of Incyte shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$199,665
Shares × reported transaction price
28 days after results of Apr 28, 2026, 63 days before results of Jul 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $97.10 on May 26, 2026, 50% above its 52-week low and 12% below its high, after a 2% rise over the previous 30 trading days
52-week range $64.93 (May 28, 2025) to $110.57 (Jan 7, 2026), 70% of the way up, from 251 adjusted closes. 30 trading days earlier: $95.55 on Apr 13, 2026. Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on May 18, 2026, 8 days before this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +5.8% | -2.5% | +8.3% |
| 30 days | +18.5% | -2.0% | +20.6% |
| 90 days | +32.0% | +1.9% | +30.1% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.